

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

-APPLICATION NO.	FILING DATE		ATTORNEY-DOCKET-NO.	CONFIRMATION NO.
10/567,279	04/19/2007	Kerstin Ehlert	Le A 36 810	9770
35969 JEEEDEN NA (35969 7590 01/09/2008 JEFFREY M. GREENMAN BAYER PHARMACEUTICALS CORPORATION			IINER
				FRONDA, CHRISTIAN L
400 MORGAN LANE WEST HAVEN, CT 06516		ART UNIT	PAPER NUMBER	
WESTIENE	WEST HIVEN, OT 00510		1652	
			MAIL DATE	DELIVERY MODE
			01/09/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•		10-11-14-1
•	Application No.	Applicant(s)
	10/567,279	EHLERT ET AL.
Office Action Summary	Examiner	Art Unit
	Christian L. Fronda	1652
The MAILING DATE of this communication Period for Reply	on appears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR IN WHICHEVER IS LONGER, FROM THE MAILI - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communicat - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, b - Any reply received by the Office later than three months after the - earned patent term adjustment. See 37 CFR 1.704(b).	NG DATE OF THIS COMMUNIC. CFR 1.136(a). In no event, however, may a reption. To period will apply and will expire SIX (6) MONTLY y statute, cause the application to become ABA	ATION. Ily be timely filed HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).
Status		
 Responsive to communication(s) filed on This action is FINAL. Since this application is in condition for a closed in accordance with the practice un 	This action is non-final.	• •
Disposition of Claims		
4) Claim(s) 1-8 is/are pending in the application Papers 4a) Of the above claim(s) is/are with significant significan	ithdrawn from consideration. d/or election requirement. aminer.	, y the Examiner.
Applicant may not request that any objection Replacement drawing sheet(s) including the answer of the control o	correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of: 1. Certified copies of the priority docu 2. Certified copies of the priority docu 3. Copies of the certified copies of the application from the International E * See the attached detailed Office action for	uments have been received. uments have been received in Apple priority documents have been resure as (PCT Rule 17.2(a)).	olication No eceived in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-94) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date		Mail Date commal Patent Application

Art Unit: 1652

DETAILED ACTION

Election/Restriction

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Invention 1 Claim(s) 1-4, drawn to a DNA material comprising the T7 promoter or xlyA promoter, ribosome binding site from a Gram-positive bacterium, and a reporter gene..

Invention 2 Claim(s) 5-8, drawn to a method to determine whether a test substance has antimicrobial activity against Gram-positive bacteria.

The inventions listed as Inventions 1 and 2 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

A same or corresponding technical feature shared among Inventions 1 and 2 is any DNA material comprising the xlyA promoter, ribosome binding site from a Gram-positive bacterium, and a reporter gene.

Sizemore et al. (J Bacteriol. 1992 May;174(9):3042-8; PTO 892) teach such DNA material, specifically, a DNA construct comprising the xylAB regulatory region fused to a lipase

Art Unit: 1652

gene which is the reporter gene. Thus, the same or corresponding technical feature is not special since it was known in the prior art and therefore cannot make a contribution over the prior art. Since the inventions lack the same or corresponding special technical feature, then the inventions listed as Invention 1 and Invention 2 are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to

Art Unit: 1652

retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272 0929. The examiner can normally be reached Monday-Thursday and alternate Fridays between 9:00AM 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura N Achutamurthy can be reached on (571)272 0928. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.

Application/Control Number: 10/567,279 Page 4

Art Unit: 1652

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Christian L. Fronda/
Patent Examiner
Art Unit 1652